Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.83 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.83 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CLTC | Q00610 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655162 | 0.82 | ESR1 (0.57) | ESR1ESR2LMNANR1H2NR1H3 | |
| SCHEMBL11863055 | 0.82 | ESR1 (0.57) | ESR1ESR2POLBLMNASCN2A | |
| SCHEMBL11305617 | 0.82 | ESR1 (0.57) | ESR1ESR2TDP1LMNANR1H2 | |
| SCHEMBL5846779 | 0.80 | LMNA (0.61) | ESR1ESR2POLBTDP1LMNA | |
| SCHEMBL11618288 | 0.78 | MASP2 (0.63) | ESR1ESR2LMNANR1H3RECQL | |
| SCHEMBL30657601 | 0.78 | ESR1 (0.59) | ESR1ESR2TDP1LMNAMEN1 | |
| SCHEMBL6563795 | 0.78 | ESR1 (0.59) | ESR1ESR2TDP1LMNAMEN1 | |
| SCHEMBL5579693 | 0.76 | GRM5 (0.57) | ESR1ESR2POLBMEN1KMT2A | |
| SCHEMBL4620082 | 0.76 | RECQL (0.59) | ESR1ESR2POLBTDP1CLTC | |
| SCHEMBL29895481 | 0.76 | RECQL (0.59) | ESR1ESR2POLBTDP1CLTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | US | disclosed |
| EP-1341768-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046168-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ESR2, ESRRA, ESRRB | ESR1 6/4885ESR2 1/4885POLB 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.